Kyverna Therapeutics, Inc.
Developing CAR T-cell therapies for durable remission in autoimmune diseases.
KYTX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US5019761049
- LEI:
- Country:
- United States of America
- Address:
- 5980 HORTON STREET, 94608 EMERYVILLE
- Website:
- https://kyvernatx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering Chimeric Antigen Receptor (CAR) T-cell therapies designed to achieve deep B cell depletion, reset the immune system, and induce durable, treatment-free remission from a single infusion. Its pipeline includes both autologous (e.g., KYV-101) and allogeneic (e.g., KYV-201) product candidates. Kyverna's investigational therapies are in clinical trials for various B cell-driven autoimmune diseases, including lupus nephritis, multiple sclerosis, myasthenia gravis, and systemic sclerosis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Kyverna Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kyverna Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kyverna Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
